Literature DB >> 498415

Comparative study in mice of the toxicity, pharmacology, and therapeutic activity of daunorubicin-DNA and doxorubicin-DNA complexes.

D Deprez-De Campeneere, R Baurain, M Huybrechts, A Trouet.   

Abstract

We have compared the toxicologic, pharmacologic, and therapeutic properties of the DNA complexes of daunorubicin and doxorubicin, after intravenous (IV) administration into mice. The overall toxicity of doxorubicin is significantly reduced after IV injection as a DNA complex while daunorubicin-DNA is as toxic as free daunorubicin. On hemopoietic stem cells, daunorubicin-DNA was found to be more cytotoxic than daunorubicin, while the opposite was observed with doxorubicin and doxorubicin-DNA. Both complexes are more effective than the corresponding free drugs on the L1210 murine leukemia, when given IV at equitoxic doses. The tissue uptake in mice, after IV administration, is generally lower when the drugs are given bound to DNA. The stability of the two DNA complexes is very different in the bloodstream: daunorubicin-DNA behaves more like a prodrug of daunorubicin, while doxorubicin-DNA, remaining stable in the bloodstream, meets much more the requirements of an ideal drug-macromoleculare carrier entity.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 498415     DOI: 10.1007/bf00253101

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  10 in total

1.  A direct measurement of the radiation sensitivity of normal mouse bone marrow cells.

Authors:  J E TILL; E A McCULLOCH
Journal:  Radiat Res       Date:  1961-02       Impact factor: 2.841

2.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

3.  In vitro iodination of DNA. Maximizing iodination while minimizing degradation; use of buoyant density shifts for DNA-DNA hybrid isolation.

Authors:  J M Orosz; J G Wetmur
Journal:  Biochemistry       Date:  1974-12-31       Impact factor: 3.162

4.  Experimental leukemia chemotherapy with a "lysosomotropic" adriamycin-DNA complex.

Authors:  A Trouet; D Deprez-de Campeneere; M de Smedt-Malengreaux; G Atassi
Journal:  Eur J Cancer       Date:  1974-07       Impact factor: 9.162

5.  Chemotherapy through lysosomes with a DNA-daunorubicin complex.

Authors:  A Trouet; D Deprez-de Campeneere; C De Duve
Journal:  Nat New Biol       Date:  1972-09-27

6.  Iodination of nucleic acids in vitro.

Authors:  S L Commerford
Journal:  Biochemistry       Date:  1971-05-25       Impact factor: 3.162

7.  Immunochemical quantitation of antigens by single radial immunodiffusion.

Authors:  G Mancini; A O Carbonara; J F Heremans
Journal:  Immunochemistry       Date:  1965-09

8.  Growth of stem cell concentration in diffusion chambers (DC).

Authors:  P Quesenberry; E Niskanen; M Symann; D Howard; M Ryan; J Halpern; F Stohlman
Journal:  Cell Tissue Kinet       Date:  1974-07

9.  Determination of daunorubicin, doxorubicin and their fluorescent metabolites by high-pressure liquid chromatography: plasma levels in DBA2 mice.

Authors:  R Baurain; D Deprez-De Campeneere; A Trouet
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

10.  Survival of hematopoietic and lymphoma colony-forming cells in vivo following the administration of a variety of alkylating agents.

Authors:  F A Valeriote; S J Tolen
Journal:  Cancer Res       Date:  1972-03       Impact factor: 12.701

  10 in total
  8 in total

1.  Comparison of daunorubicin and daunorubicin-DNA complex in the treatment of acute nonlymphoblastic leukemia.

Authors:  C Paul; M Björkholm; I Christenson; L Engstedt; G Gahrton; R Hast; G Holm; A Killander; B Lantz; D Lockner; B Lönnqvist; H Mellstedt; J Palmblad; C Peterson; B Simonsson; A M Stalfelt; A M Udén; B Wadman; G Oberg
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

2.  DNA-binding parameters of daunorubicin and doxorubicin in the conditions used for studying the interaction of anthracycline-DNA complexes with cells in vitro.

Authors:  Y J Schneider; R Baurain; A Zenebergh; A Trouet
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

3.  Daunorubicin-DNA and doxorubicin-DNA. A review of experimental and clinical data.

Authors:  A Trouet; D Deprez-De Campeneere
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

4.  Plasma levels of doxorubicin after IV bolus injection and infusion of the doxorubicin-DNA complex in rabbits and man. Comparison with free doxorubicin.

Authors:  R Baurain; D Deprez-De Campeneere; A Zenebergh; A Trouet
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

5.  Leukemic cell versus plasma levels of daunorubicin and daunorubicinol after infusion of daunorubicin as free drug or the DNA complex.

Authors:  B Andersson; M Beran
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

6.  Synthesis and biological activities of a 3'-azido analogue of Doxorubicin against drug-resistant cancer cells.

Authors:  Shuwen Yu; Guisheng Zhang; Wenpeng Zhang; Huanhua Luo; Liyun Qiu; Qingfeng Liu; Duxin Sun; Peng-George Wang; Fengshan Wang
Journal:  Int J Mol Sci       Date:  2012-03-19       Impact factor: 6.208

7.  Antitumour activity and pharmacokinetics of niosome encapsulated adriamycin in monolayer, spheroid and xenograft.

Authors:  D J Kerr; A Rogerson; G J Morrison; A T Florence; S B Kaye
Journal:  Br J Cancer       Date:  1988-10       Impact factor: 7.640

8.  Isolated cell-bound membrane vesicles (CBMVs) as a novel class of drug nanocarriers.

Authors:  Yang Zhang; Yang Liu; Wendiao Zhang; Qisheng Tang; Yun Zhou; Yuanfang Li; Tong Rong; Huaying Wang; Yong Chen
Journal:  J Nanobiotechnology       Date:  2020-05-06       Impact factor: 10.435

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.